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Abstract
Urinary type IV collagen (U-Col4) and albumin excretion is evaluated to monitor the develop-
ment of diabetic kidney disease. However, U-Col4 excretion in the general population without
diabetes has not yet been fully elucidated. In this study, 1067 participants without diabetes and
with urinary albumin-creatinine ratio <300 mg/gCr (normo- or microalbuminuria) who under-
went an annual health examination in 2004 were enrolled and observed for 5 years. They were
divided according to the amount of U-Col4 or urinary albumin excreted. The decline in esti-
mated glomerular filtration rate (eGFR) was calculated. In participants with eGFR80 mL/min,
abnormal U-Col4 excretion was indicated as a significant independent risk factor for 10%
eGFR change per year, which is one of the prognostic factors for the development of end-
stage kidney disease. Moreover, in contrast to urinary albumin excretion, U-Col4 excretion was
not related to age or kidney function, suggesting that some individuals with abnormal U-Col4
excretion can have an independent hidden risk for the development of kidney dysfunction. In
conclusion, it is important to measure U-Col4 excretion in the general population without diabe-
tes to determine changes in renal features in every individual and help detect future complica-
tions such as diabetic kidney disease. If U-Col4 excretion is abnormal, kidney manifestation
should be carefully followed up, even if the kidney function and urinalysis findings are normal.
Introduction
Urinary type IV collagen (U-Col4) and albumin excretion is used to monitor the development
of diabetic nephropathy and is associated with the disease progression [1–4]. Microalbumi-
nuria was also included in the definition of generic chronic kidney disease (CKD) in the
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original classification schema of the Kidney Disease Outcomes Quality Initiative (KDOQI) of
the National Kidney Foundation (NKF) in 2002 [5]. Regardless of the underlying mechanisms
and interpretation of the pathophysiologic meaning of albuminuria, important associations
exist between the quantities of albumin excreted in the urine and progressive CKD and cardio-
vascular events [6]. In contrast, U-Col4 excretion in patients with nondiabetic kidney disease
and the general population has not yet been fully elucidated. Furumatsu et al. evaluated
U-Col4 in nondiabetic kidney disease and reported that elevation of U-Col4 was distinctively
observed in the patients with membranous nephropathy and anti-neutrophil cytoplasmic anti-
body-associated glomerulonephritis [7]. We previously examined the U-Col4-creatinine ratio
(U-Col4CR) in the general population. The mean U-Col4CR and urinary albumin-creatinine
ratio (ACR) values increased in individuals with estimated glomerular filtration rate (eGFR)
<60 mL/min/1.73m2 compared to that in individuals with eGFR of 60–89 mL/min/1.73m2
and90 mL/min/1.73m2. However, the incidence rate of abnormal U-Col4CR was around
15–20%, and was similar among individuals with eGFR<60 mL/min/1.73m2, 60–89 mL/min/
1.73m2, and90 mL/min/1.73m2, whereas the incidence rate of high ACR increased signifi-
cantly in individuals with low eGFR values [8]. To our best knowledge, no study has investi-
gated whether abnormal U-Col4CR in the general population is associated with a decline in
the eGFR.
Therefore, in this study, we examined the relationship between U-Col4CR and ACR and
eGFR change to clarify their role in the progression of kidney dysfunction in the general
population.
Materials and methods
Ethical approval
This study was approved by the Ethics Committee of the Arita-cho, HuBit genomics, Inc. and
was performed in compliance with the Helsinki Declaration. Written informed consent was
obtained from all participants.
Design and subjects
In 2004, 1376 participants in the town of Arita in Japan were registered who underwent an
annual health examination and gave us written informed consent. Their health examinations
were continued annually. We excluded the participants: (i) if they did not revisit their annual
health examinations until 2009 (n = 198) because we could not calculate their declines in
eGFR: (ii) if they exhibited ACR300 mg/gCr (macroalbuminuria) (n = 7) because the num-
ber of participants with macroalbuminuria was not enough to analyze the prognosis statisti-
cally: (iii) if they had taken diabetes medications and/or their HbA1c (NGSP) was6.5% and/
or non-fasting blood glucose level was200 mg/dL (n = 104) because we focused on the prog-
nosis of participants without diabetes [9]. Finally, 1067 participants were enrolled in this study
(Fig 1). Of the 1067 participants, 335 got an annual health examination once (290 in 2005, 18
in 2006, 17 in 2007, 2 in 2008, 8 in 2009), 152 got twice, 223 got 3 times, 155 got 4 times and
202 got 5 times for the period of 5 year. The follow-up year was 3.1 ± 1.6 (mean ± SD) years.
As described previously [8], this study is a community-based survey that consisted of a self-
administered questionnaire on lifestyle, medical histories, anthropometrical measurements,
and collections of blood and urine specimens from participants. All relevant data derived from
their annual health examinations can be found in S1 File.
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Questionnaires, blood pressure measurement and body mass index
Participants used a self-report questionnaire to document medical history and lifestyle. They
answered whether they had ever been treated with any of the followings: diabetes mellitus,
hypertension, and hyperlipidemia. They answered alcohol intake (drinker or non-drinker),
smoking habit (smoker or non-smoker). Systolic and diastolic blood pressures were measured
by using an automatic oscillometric method using HEM-780 (OMRON Corporation, Kyoto,
Japan) in the sitting position after at least 5 minutes rest. Measurement was performed twice,
and the mean value was used for statistical analysis. Body mass index was calculated by divid-
ing weight (kg) by height (m) squared.
Laboratory methods and estimation of glomerular filtration rate
Blood samples were taken from all participants for the assessment of laboratory parameters
once during a health examination. Serum creatinine (Cr) concentration was measured by the
Jaffe method using an AU5431 auto analyzer (Olympus Corporation, Tokyo, Japan). The value
of serum Cr was corrected by subtracting 0.2 mg/dL to that measured by the enzymatic
method [10]. eGFR of each participant was calculated from corrected serum Cr and age by
using the 3-variable Japanese equation as follows [11].
eGFR ðmL=min=1:73m2Þ ¼ 194 X Age  0:287 X Cr ðmg=dLÞ  1:094 ðX 0:739 if femaleÞ:
In order to increase the accuracy of individual eGFR change, eGFR data shown in this anal-
ysis are the eGFR indexed by body surface area calculated by the Du Bois formula [12]. To cal-
culate a decline in eGFR per year, a simple linear regression line was estimated by the least
squares method using all eGFR measurements for each participant (2 to 6 samples, mean: 3.75
samples). The calculated eGFR in each year was determined using the linear regression line.
Last eGFR was defined as the latest calculated eGFR during the observation period. If the latest
calculated eGFR was below 0 mL/min, the calculated eGFR before the latest calculated eGFR
Fig 1. Study participants.
https://doi.org/10.1371/journal.pone.0195523.g001
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was used as last eGFR (n = 11). %eGFR change per year was calculated as follows [9].
%eGFR change per year ð%Þ
¼ ðlast eGFR   eGFR in 2004Þ= eGFR in 2004= ðthe year of last eGFR   2004Þ X 100:
HbA1c (the Japan Diabetes Society: JDS) was measured by high performance liquid chro-
matography. HbA1c (JDS) was converted to HbA1c (NGSP) according to the equation:
HbA1c (NGSP) (%) = 1.02 X HbA1c (JDS) (%)+ 0.25 [13].
Urine samples were collected from participants at their homes and transported to the labora-
tory. Urinary Cr concentration was measured by the enzymatic method (Shino-Test Corporation,
Tokyo, Japan). Urinary albumin concentration was measured by a turbidimetric immunoassay
(Wako Diagnostics, Osaka, Japan). ACR was calculated as urinary albumin concentration divided
by urinary Cr concentration. Microalbuminuria was defined as ACR of 30–300 mg/gCr [14].
U-Col4 level was measured by a one-step sandwich enzyme immunoassay using two monoclonal
antibodies against the 7S domain and the triple helix domain of human placental type IV collagen
(Daiichi Fine Chemical Co Ltd., Toyama, Japan) [15,16]. U-Col4CR was determined as U-Col4
concentration divided by urinary Cr concentration. The normal cut-off range of U-Col4CR was
<8.2 μg/gCr and<9.4 μg/gCr for males and females, respectively, determined by using the urine
samples of 442 healthy adults (age, 20–70 years) who yielded normal results on both physical
examination and laboratory analyses as shown in our previous report [8].
Statistical analysis
The characteristics of multiple groups were analyzed using one-way factorial ANOVA or Krus-
kal-Wallis test. The declines in eGFR among eGFR groups were compared by using Dunnett’s
test. The characteristics of two groups were analyzed using student’s t-test or Wilcoxon rank sum
test. F-test was used for comparing the factors of total deviation. Categorical data were compared
by Fisher’s exact test. Risk factors for 10% eGFR change per year were evaluated by a multivariate
logistic regression analysis using demographic and clinical characteristics. If there were strong
correlations (rs>0.5) between characteristics, one representative variable was chosen to the anal-
ysis, that is ALT and hemoglobin, which were correlated with AST, γ-GTP and red blood cell
count, hematocrit, respectively (data not shown). Non-fasting blood glucose level was deleted
because of the presence of HbA1c. Serum Cr concentration was deleted because participants
were already divided based on eGFR. Consequently, U-Col4CR, ACR (normoalbuminuria vs
microalbuminuria or the actual value of ACR), age, gender, body mass index, drinker, smoker,
systolic blood pressure, diastolic blood pressure, HbA1c, ALT, total cholesterol, triglyceride,
HDL-cholesterol and hemoglobin were used for the analysis. Kaplan-Meier curves were plotted
to estimate the prognostic value of abnormal U-Col4CR (vs. normal U-Col4CR) or microalbumi-
nuria (vs. normoalbuminuria) for a decline in eGFR. The event was defined as the first occur-
rence of 10% eGFR change per year (90, 80, 70, 60, 50% of eGFR in 2004 in 1, 2, 3, 4, 5 years,
respectively) in the actual eGFR value of participants with 10% eGFR change per year. Log-Rank
test was used to compare the cumulative incidences of two groups. All values are expressed as
mean ± SD. Statistical analysis was performed using Windows SAS 9.4 (SAS Institute Inc., Cary,
NC, USA.). A statistical significance was defined by P less than 0.05.
Results
Study participants
A total of 1067 participants aged 20 to 91 years (mean ± SD, 61.9 ± 13.6 years) were included
in this study, with 677 participants (63.4%) being women. Of all participants, 522 (48.9%) were
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drinkers and 134 (12.6%) were smokers. Their mean age, gender distribution, and drinking
and smoking habits were similar with those in recent large Japanese community-based cohort
studies [17–19]. U-Col4CR ranged from 0.9 to 47.7 μg/gCr (6.19 ± 3.52 μg/gCr); 149 partici-
pants (14.0%) had abnormal U-Col4CR. ACR varied from 0.7 to 291.9 mg/gCr (13.66 ± 21.91
mg/gCr); 77 participants (7.2%) had microalbuminuria. Systolic and diastolic blood pressures
were 130.2 ± 21.0 and 78.0 ± 11.0 mmHg, respectively. HbA1c level was 5.45 ± 0.39%. Of the
participants, 253 (23.7%) and 95 (8.9%) underwent treatment for hypertension and hyperlipid-
emia, respectively.
Decline in eGFR in participants without diabetes with normo- or
microalbuminuria
The decline in eGFR was evaluated in this study. The participants were divided into 4 groups
based on eGFR quartiles (group 1: <58.2 mL/min, group 2: 58.2–<68.1 mL/min, group 3:
68.1–<80 mL/min, group 4:80 mL/min); participants with the highest eGFR (80 mL/min)
had a faster decline than those with eGFR<68.1 mL/min (Fig 2). Our results were consistent
with those of the previous report by Imai et al., which observed a faster decline in eGFR in the
aged group (60 years) with eGFR70 mL/min/1.73m2 than in those with eGFR of 60–69
mL/min/1.73m2 [20].
Distribution of participants with abnormal U-Col4CR or high ACR
(microalbuminuria) in each eGFR group
To examine the effect of abnormal U-Col4CR or high ACR (microalbuminuria) on a decline
in eGFR, the participants in each eGFR group were analyzed. The lower eGFR group included
more older and female participants with higher ACR and systolic blood pressure (Table 1).
Levels of HbA1c, non-fasting blood glucose, total cholesterol, triglyceride were higher, and lev-
els of ALT, hemoglobin were lower in the lower eGFR group. The number of participants
Fig 2. Decline in eGFR in participants without diabetes with normo- or microalbuminuria. Participants with the highest eGFR (80 mL/min) had a faster decline in
eGFR than those with eGFR<68.1 mL/min. Num.: Number. 95%CI: 95% confidence interval. P<0.01.
https://doi.org/10.1371/journal.pone.0195523.g002
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undergoing treatment for hypertension or hyperlipidemia was higher in the lower eGFR
group. Consequently, the participants in the lower eGFR group experienced more complica-
tions than those in the higher eGFR group. It is notable that both the mean value of U-Col4CR
and the number of participants with abnormal U-Col4CR showed no difference among the
groups.
Characteristics of participants with or without 10% of eGFR change per
year in each group
To determine the risk factors for a decline in eGFR, we divided participants in the 4 groups
mentioned previously according to the %eGFR change per year faster or slower than 10%,
because 30% eGFR change over 2 or 3 years was suggested as one of the prognostic factors for
the development of end-stage kidney disease [9, 21–24], and compared demographic and clini-
cal variables between participants with the change per year of eGFR by 10% and those without
the change (Tables 2 and 3). More participants with abnormal U-Col4CR were included in
those with the change than those without the change in group 4. ACR was significantly higher
in participants with the change in group 3 and 4. There were several other variables such as old
Table 1. Distribution of participants with abnormal urinary type IV collagen-creatinine ratio or microalbuminuria in each eGFR group.
eGFR group 1 (<58.2) 2 (<68.1) 3 (<80.0) 4 (80.0)
Number, n 266 264 270 267
U-Col4CR, μg/gCr 6.35 ± 4.16 5.98 ± 3.11 6.16 ± 3.23 6.28 ± 3.49
N, Normal, n (%) A, Abnormal, n (%) 228 (85.7%) 38 (14.3%) 230 (87.1%) 34 (12.9%) 233 (86.3%) 37 (13.7%) 227 (85.0%) 40 (15.0%)
ACR, mg/gCr 18.2 ± 31.6 13.3 ± 21.3 11.1± 9.5 12.1± 19.0
L, Normo, n (%) M, Micro, n (%) 237 (89.1%) 29 (10.9%) 245 (92.8%) 19 (7.2%) 256 (94.8%) 14 (5.2%) 252 (94.4%) 15 (5.6%)
Age, years 70.4 ± 8.4 65.4 ± 10.5 60.6 ± 11.9 51.2 ± 14.5
Female, % 195 (73.3%) 171 (64.8%) 160 (59.3%) 151 (56.6%)
BMI, kg/m2 22.13 ± 3.09 22.41 ± 2.71 22.44 ± 2.72 22.65 ± 3.19
Drinker, n (%) 92 (34.6%) 113 (42.8%) 142 (52.6%) 175 (65.5%)
Smoker, n (%) 15 (5.6%) 19 (7.2%) 41 (15.2%) 59 (22.1%)
SBP (mmHg) 134.7 ± 21.3 131.1 ± 20.8 129.7 ± 19.6 125.4 ± 21.4
DBP (mmHg) 78.8 ± 10.9 78.4 ± 10.3 78.1 ± 11.1 76.9 ± 11.5
HbA1c (%) 5.55 ± 0.36 5.50 ± 0.37 5.42 ± 0.39 5.33 ± 0.41
NFBG (mg/dL) 85.5 ± 13.3 83.3 ± 9.5 84.2 ± 12.6 82.2 ± 10.8
ALT (IU/L) 18.9 ± 8.6 20.8 ± 11.7 22.3 ± 13.2 22.2 ± 13.5
T-chol (mg/dL) 202.7 ± 29.8 200.3 ± 30.8 195.3 ± 34.8 189.1 ± 31.4
HDL-C (mg/dL) 54.6 ± 11.5 54.0 ± 12.1 55.5 ± 13.3 54.8 ± 13.0
TG (mg/dL) 103.7 ± 50.0 102.0 ± 56.6 103.5 ± 65.9 93.6 ± 56.5
Cre (mg/dL) 0.81 ± 0.20 0.70 ± 0.14 0.65 ± 0.14 0.58 ± 0.14
Hb (g/dL) 13.01 ± 1.33 13.39 ± 1.24 13.57 ± 1.55 13.60 ± 1.76
HT. treat. 102 (38.3%) 70 (26.5%) 42 (15.6%) 39 (14.6%)
HL. treat. 37 (13.9%) 30 (11.4%) 18 (6.7%) 10 (3.7%)
eGFR: Estimated glomerular filtration rate. Group 1: <58.2 mL/min. Group 2: 58.2-<68.1 mL/min. Group 3: 68.1-<80.0 mL/min. Group 4:80.0 mL/min. U-Col4CR:
Urinary type IV collagen-creatinine ratio. N, Normal: Normal urinary type IV collagen-creatinine ratio. A, Abnormal: Abnormal urinary type IV collagen-creatinine
ratio. ACR: Urinary albumin-creatinine ratio. L, Normo: Normoalbuminuria. M, Micro: Microalbuminuria. BMI: Body mass index. SBP: Systolic blood pressure. DBP:
Diastolic blood pressure. NFBG: Non-fasting blood glucose level. T-chol: Total cholesterol. HDL-C: HDL-cholesterol. TG: Triglyceride. Cre: Creatinine. Hb:
Hemoglobin. HT. treat.: Participants underwent treatment for hypertension. HL. treat.: Participants underwent treatment for hyperlipidemia.
: P<0.01.
: P<0.05
https://doi.org/10.1371/journal.pone.0195523.t001
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age (group 1,2,3) and high systolic blood pressure (group 1) related to participants with the
change.
Abnormal U-Col4CR was a significant independent risk factor for 10% of
eGFR change per year in group 4
Odds ratios of U-Col4CR and ACR for 10% of eGFR change per year were determined in par-
ticipants with normo- or microalbuminuria in a multivariate logistic regression analysis.
Abnormal U-Col4CR was a significant risk factor for 10% of eGFR change per year in group 4,
even after adjustment for demographic and clinical characteristics, whereas microalbuminuria
was not a significant risk factor in all groups (Table 4).
Abnormal U-Col4CR was also a significant risk factor for 10% of eGFR change per year,
even after adjustment for the characteristics in participants with normoalbuminuria in group
4 only (data not shown). If the odds ratio of the actual value of ACR was determined in the
same analysis, abnormal U-Col4CR was still a significant risk factor for 10% of eGFR change
per year in group 4. ACR was revealed as a significant risk factor for 10% of eGFR change per
year in group 3, even after adjustment for the characteristics (Table 5).
Table 2. Characteristics of participants with or without 10% of eGFR change per year in each group.
eGFR group 1 (<58.2) 2 (58.2-<68.1)
%eGFR change per year -10% >-10% -10% >-10%
Number, n 25 241 14 250
U-Col4CR, μg/gCr 6.96 ± 3.37 6.28 ± 4.24 7.25 ± 5.77 5.91 ± 2.90
N,Normal, n (%) A,Abnormal,n(%) 19 (76.0%) 6 (24.0%) 209 (86.7%) 32 (13.3%) 11 (78.6%) 3 (21.4%) 219 (87.6%) 31 (12.4%)
ACR, mg/gCr 23.9 ± 33.1 17.6 ± 31.5 18.8 ±18.6 13.0 ± 21.4
L, Normo, n (%) M, Micro, n (%) 22 (88.0%) 3 (12.0%) 215 (89.2%) 26 (10.8%) 11 (78.6%) 3 (21.4%) 234 (93.6%) 16 (6.4%)
Age, years 78.6 ± 4.3 69.6 ± 8.3 74.6 ± 15.7 64.9 ± 9.9
Female, % 19 (76.0%) 176 (73.0%) 5 (35.7%) 166(66.4%)
BMI, kg/m2 21.58 ± 2.94 22.19 ± 3.10 20.79 ± 3.05 22.50 ±2.66
Drinker, n (%) 5 (20.0%) 87 (36.1%) 6 (42.9%) 107 (42.8%)
Smoker, n (%) 2 (8.0%) 13 (5.4%) 1 (7.1%) 18 (7.2%)
SBP (mmHg) 147.6 ± 22.0 133.4 ± 20.8 133.1 ± 22.1 131.0 ± 20.8
DBP (mmHg) 82.5 ± 13.5 78.4 ± 10.6 77.6 ± 7.0 78.5 ± 10.5
HbA1c (%) 5.64 ± 0.42 5.55 ± 0.36 5.48 ± 0.38 5.50 ± 0.37
NFBG (mg/dL) 83.8 ± 8.3 85.7 ± 13.7 84.4 ± 12.0 83.2 ± 9.4
ALT (IU/L) 21.4 ± 13.6 18.6 ± 7.8 19.1 ± 11.4 20.9 ± 11.8
T-chol (mg/dL) 190.1 ± 25.0 204.1 ± 30.0 181.1 ± 31.6 201.3 ±30.5
HDL-C (mg/dL) 52.4 ± 10.6 54.8 ± 11.6 53.9 ± 9.1 54.0 ± 12.2
TG (mg/dL) 111.9 ± 58.4 102.9 ± 49.1 80.8 ± 43.4 103.2 ± 57.1
Hb (g/dL) 12.54 ± 1.32 13.06 ± 1.33 13.44 ± 1.41 13.39 ± 1.23
HT. treat. 17 (68.0%) 85 (35.3%) 4 (28.6%) 66 (26.4%)
HL. treat. 3 (12.0%) 34 (14.1%) 0 (0.0%) 30 (12.0%)
eGFR: Estimated glomerular filtration rate. Group 1: <58.2 mL/min. Group 2: 58.2-<68.1 mL/min. U-Col4CR: Urinary type IV collagen-creatinine ratio. N, Normal:
Normal urinary type IV collagen-creatinine ratio. A, Abnormal: Abnormal urinary type IV collagen-creatinine ratio. ACR: Urinary albumin-creatinine ratio. L, Normo:
Normoalbuminuria. M, Micro: Microalbuminuria. BMI: Body mass index. SBP: Systolic blood pressure. DBP: Diastolic blood pressure. NFBG: Non- fasting blood
glucose level. T-chol: Total cholesterol. HDL-C: HDL-cholesterol. TG: Triglyceride. Hb: Hemoglobin. HT. treat.: Participants underwent treatment for hypertension.
HL. treat.: Participants underwent treatment for hyperlipidemia.
: P<0.01.
: P<0.05.
https://doi.org/10.1371/journal.pone.0195523.t002
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Kaplan-Meier curves to evaluate the prognostic value of U-Col4CR or ACR
for 10% eGFR change per year
In each group, Kaplan-Meier curves were plotted to evaluate the prognostic value of
U-Col4CR or ACR for 10% eGFR change per year. Abnormal U-Col4CR in group 4 and
microalbuminuria in group 2 were statistically significant for the prediction of 10% eGFR
change per year (Fig 3).
Discussion
In this study, we demonstrated that U-Col4CR was a significant independent risk factor for
the decline in eGFR in the Japanese general population without diabetes who had ACR<300
mg/gCr and eGFR80 mL/min. To our knowledge, this is the first report that showed the
importance of U-Col4CR measurement even in the general population without diabetes.
A novel finding of this study is that abnormal U-Col4CR can be one of the prognostic fac-
tors for kidney deterioration in individuals without diabetes and apparent proteinuria with
normal kidney function. The usefulness of U-Col4CR as well as ACR to monitor the
Table 3. Characteristics of participants with or without 10% of eGFR change per year in each group.
eGFR group 3 (68.1-<80.0) 4 (80.0)
%eGFR change per year -10% >-10% -10% >-10%
Number, n 13 257 15 252
U-Col4CR, μg/gCr 5.78 ± 2.62 6.18 ± 3.26 8.47 ± 4.75 6.15 ± 3.37
N,Normal, n (%) A,Abnormal,n(%) 12 (92.3%) 1 (7.7%) 221 (86.0%) 36 (14.0%) 8 (53.3%) 7 (46.7%) 219 (86.9%) 33 (13.1%)
ACR, mg/gCr 16.0 ± 9.5 10.9 ± 9.4 18.6 ± 16.3 11.7 ± 19.1
L, Normo, n (%) M, Micro, n (%) 12 (92.3%) 1 (7.7%) 244 (94.9%) 13 (5.1%) 13 (86.7%) 2 (13.3%) 239 (94.8%) 13 (5.2%)
Age, years 71.5 ± 7.8 60.0 ± 11.8 52.8 ± 19.3 51.1 ± 14.3
Female, % 6 (46.2%) 154 (59.9%) 10 (66.7%) 141 (56.0%)
BMI, kg/m2 22.05 ± 2.53 22.46 ± 2.73 22.69 ± 2.88 22.64 ± 3.21
Drinker, n (%) 7 (53.8%) 135 (52.5%) 11 (73.3%) 164 (65.1%)
Smoker, n (%) 3 (23.1%) 38 (14.8%) 5 (33.3%) 54 (21.4%)
SBP (mmHg) 136.0 ± 14.7 129.4 ± 19.8 133.4 ± 26.9 125.0 ± 21.0
DBP (mmHg) 79.8 ± 10.5 78.0 ± 11.2 78.5 ± 11.5 76.8 ± 11.5
HbA1c (%) 5.35 ± 0.42 5.42 ± 0.39 5.21 ± 0.50 5.34 ± 0.41
NFBG (mg/dL) 82.8 ± 10.1 84.3 ± 12.7 79.5 ± 7.2 82.4 ± 11.0
ALT (IU/L) 15.4 ± 4.5 22.6 ±13.4 21.3 ± 13.4 22.3 ± 13.6
T-chol (mg/dL) 182.8 ± 25.5 196.0 ± 35.1 175.5 ± 26.9 189.9 ± 31.5
HDL-C (mg/dL) 51.0 ± 13.7 55.7 ± 13.2 49.2 ± 9.3 55.1 ± 13.1
TG (mg/dL) 100.2 ± 67.1 103.7 ± 66.0 100.5 ± 65.8 93.2 ± 56.0
Hb (g/dL) 13.09 ± 1.64 13.60 ± 1.55 13.90 ± 1.83 13.58 ± 1.76
HT. treat. 1 (7.7%) 41 (16.0%) 6 (40.0%) 33 (13.1%)
HL. treat. 1 (7.7%) 17 (6.6%) 0 (0.0%) 10 (4.0%)
eGFR: Estimated glomerular filtration rate. Status 3: 68.1-<80.0 mL/min. Status 4:80.0 mL/min. U-Col4CR: Urinary type IV collagen-creatinine ratio. N, Normal:
Normal urinary type IV collagen-creatinine ratio. A, Abnormal: Abnormal urinary type IV collagen-creatinine ratio. ACR: Urinary albumin-creatinine ratio. L, Normo:
Normoalbuminuria. M, Micro: Microalbuminuria. BMI: Body mass index. SBP: Systolic blood pressure. DBP: Diastolic blood pressure. NFBG: Non- fasting blood
glucose level. T-chol: Total cholesterol. HDL-C: HDL-cholesterol. TG: Triglyceride. Hb: Hemoglobin. HT. treat.: Participants underwent treatment for hypertension.
HL. treat.: Participants underwent treatment for hyperlipidemia.
: P<0.01.
: P<0.05.
https://doi.org/10.1371/journal.pone.0195523.t003
Urinary type IV collagen excretion in the Japanese general population without diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0195523 April 6, 2018 8 / 14
development of diabetic nephropathy is well recognized. However, the importance of
U-Col4CR in the general population has not been determined yet. We investigated the possible
risk factors, including U-Col4CR and ACR, for the decline in eGFR in the general population
without diabetes with normo- or microalbuminuria. Several reports have described the risk
factors for kidney deterioration in patients with CKD, but few have investigated or discussed
the eGFR change in individuals with eGFR60 mL/min/1.73m2 [9,20–24]. Therefore, we
focused on the decline of eGFR in the general population without diabetes and apparent pro-
teinuria with normal kidney function. Abnormal U-Col4CR was identified as a prognostic fac-
tor for the decline in eGFR in individuals with eGFR80 mL/min (Tables 4 and 5, Fig 3).
Conversely, microalbuminuria was not a significant risk factor for the decline in eGFR in
the general population without diabetes (Table 4). However, the definition of microalbumi-
nuria as30 mg/gCr may not be precise. This is consistent with those of other previous
reports. Several studies have shown that ACR reference values have inherent racial disparities
resulting from either albumin [25] or creatinine excretion [26]. Using the Caucasian data sets,
KDOQI recommended ACR reference values of<17 mg/gCr for males and<25 mg/gCr for
females [27]. Thus, we recognize the importance of ACR as well as U-Col4CR as one of the
possible prognostic factors for the decline in eGFR in the general population without diabetes
Table 4. Odds ratios of urinary type IV collagen-creatinine ratio (U-Col4CR) and urinary albumin-creatinine ratio (ACR) for 10% of eGFR change per year.
eGFR group Variable OR 95%CI P Adj. OR 95%CI P
1 (<58.2) U-Col4CR A (vs. N) 2.089 0.756–5.774 0.156 2.175 0.654–7.239 0.205
ACR M (vs. L) 0.931 0.250–3.467 0.915 0.428 0.076–2.406 0.335
2 (<68.1) U-Col4CR A (vs. N) 1.647 0.420–6.457 0.474 1.227 0.211–7.131 0.820
ACR M (vs. L) 3.697 0.917–14.909 0.066 4.436 0.685–28.740 0.118
3 (<80.0) U-Col4CR A (vs. N) 0.476 0.058–3.874 0.488 0.318 0.026–3.954 0.373
ACR M (vs. L) 1.808 0.211–15.477 0.589 2.868 0.183–45.012 0.453
4 (80.0) U-Col4CR A (vs. N) 5.516 1.787–17.024 0.003 7.086 1.640–30.611 0.009
ACR M (vs. L) 1.331 0.241–7.351 0.743 1.623 0.226–11.650 0.623
OR: Odds ratio. Adj. OR: Adjusted odds ratio. 95%CI: 95% confidence interval. A: Abnormal urinary type IV collagen-creatinine ratio. N: Normal urinary type IV
collagen-creatinine ratio. M: Microalbuminuria. L: Normoalbuminuria. The variables adjusted for: age, gender, body mass index, drinker, smoker, systolic blood
pressure, diastolic blood pressure, HbA1c, ALT, total cholesterol, triglyceride, HDL-cholesterol, hemoglobin.
https://doi.org/10.1371/journal.pone.0195523.t004
Table 5. Odds ratios of urinary type IV collagen-creatinine ratio (U-Col4CR) and urinary albumin-creatinine ratio (ACR) for 10% of eGFR change per year in par-
ticipants with normoalbuminuria only.
eGFR group Variable OR 95%CI P Adj. OR 95%CI P
1 (<58.2) U-Col4CR A (vs. N) 2.786 0.956–8.121 0.061 3.005 0.815–11.078 0.098
ACR mg/gCr 1.056 0.994–1.122 0.077 1.013 0.937–1.094 0.752
2 (<68.1) U-Col4CR A (vs. N) 0.704 0.086–5.735 0.743 0.842 0.074–9.552 0.890
ACR mg/gCr 1.045 0.947–1.154 0.381 1.056 0.936–1.193 0.374
3 (<80.0) U-Col4CR A (vs. N) 0.511 0.061–4.290 0.536 0.133 0.005–3.902 0.242
ACR mg/gCr 1.132 1.044–1.229 0.003 1.197 1.049–1.367 0.008
4 (80.0) U-Col4CR A (vs. N) 5.439 1.627–18.183 0.006 12.838 2.133–77.264 0.005
ACR mg/gCr 1.105 1.020–1.196 0.015 1.101 0.992–1.223 0.071
OR: Odds ratio. Adj. OR: Adjusted odds ratio. 95%CI: 95% confidence interval. A: Abnormal urinary type IV collagen-creatinine ratio. N: Normal urinary type IV
collagen-creatinine ratio. The variables adjusted for: age, gender, body mass index, drinker, smoker, systolic blood pressure, diastolic blood pressure, HbA1c, ALT, total
cholesterol, triglyceride, HDL-cholesterol, hemoglobin.
https://doi.org/10.1371/journal.pone.0195523.t005
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(Table 5). However, albuminuria can be affected by several CKD-related factors inclusive of
aging, metabolic syndrome, hypertension, and diabetes, taking the ACR values into account in
eGFR groups (Table 1). This hypothesis is supported by previous results of studies on the vari-
ous causes of albuminuria including hemodynamic, permeability, and histological abnormali-
ties [28–32].
Interestingly, the number of participants with abnormal U-Col4CR was not different
among eGFR groups, whereas the number of participants with microalbuminuria was higher
in low eGFR groups (Table 1). U-Col4CR was not affected by hypertension and aging com-
pared with ACR. We speculate that some individuals have kidney structural or hemodynamic
impairment related to abnormal U-Col4CR, although the cause of kidney impairment is
unknown. This hypothesis is consistent with that of a previous report by Furumatsu et al. [7],
which indicated that not a few patients with representative nephrotic syndrome and glomeru-
lonephritis had abnormal U-Col4CR. This kidney impairment can appear as a prognostic fac-
tor for kidney dysfunction aside from other well-known risk factors such as aging, metabolic
syndrome, hypertension and diabetes. The mechanism of abnormal U-Col4 excretion in non-
diabetic kidney disease is apparently different from that of albuminuria, but this has not been
clarified yet. In our study, 77 participants had microalbuminuria and 149 exhibited abnormal
U-Col4CR, but only 28 showed both microalbuminuria and abnormal U-Col4CR (data not
shown). In another Japanese cross-sectional study, of the 1079 Japanese general population
without diabetes aged 40 to 65 years who had normal urinalysis findings and serum Cr con-
centration <1.5 mg/dL, 54 had ACR>37 mg/gCr and 54 exhibited U-Col4CR >7.9 μg/gCr.
However, only 7 participants showed both abnormal ACR and U-Col4CR [33]. Abnormal
U-Col4 excretion in diabetes indicated the development of glomerular matrix accumulation,
which has been shown to result in compromised renal filtration function. A study investigating
U-Col4 excretion in patients with type 1 or type 2 diabetes showed a significant inverse corre-
lation between the reciprocal of the serum Cr concentration and U-Col4 excretion, irrelevantly
to the degree of albuminuria [34]. In addition, Banu et al. reported that U-Col4 excretion was
related to not only albuminuria but also to renal tubular damage markers such as urinary N-
acetyl-β-D-glucosaminidase and alpha1-microglobulin in patients with type 2 diabetes. [35].
Therefore, unlike albuminuria, abnormal U-Col4 excretion could likely reflect histological kid-
ney damage related to an impaired balance between collagen IV synthesis and degradation in
glomeruli and tubules simply, although only a few evidences indicated the association of
U-Col4 excretion with pathological kidney damage in human nondiabetic kidney diseases. For
instance, Enomoto et al. reported that renovascular stiffness, which is probably due to glomer-
ulosclerosis, was correlated with U-Col4 excretion in patients with essential hypertension [36].
Consequently, we could show that U-Col4CR is one of the possible prognostic factors for the
decline in eGFR in the general population without diabetes, independent of albuminuria. We
believe that U-Col4CR during a health examination should be measured to reveal an indepen-
dent hidden risk for the development of kidney dysfunction and help detect future complica-
tions such as diabetic kidney disease in every individual.
This study has some limitations. The equation for calculating eGFR is not very accurate for
assessing GFR60 ml/min/1.73m2 [11, 37], and this equation was demonstrated by evaluating
the hospitalized patients with CKD. Therefore, it is inappropriate to apply the eGFR equation
Fig 3. Kaplan-Meier curves to evaluate the prognostic value of urinary type IV collagen-creatinine ratio (U-Col4CR) or
urinary albumin-creatinine ratio (ACR) for 10% eGFR change per year. A: Abnormal urinary type IV collagen-creatinine
ratio. N: Normal urinary type IV collagen-creatinine ratio. M: Microalbuminuria. L: Normoalbuminuria.
https://doi.org/10.1371/journal.pone.0195523.g003
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to estimate kidney function in the general population [11]. However, using the eGFR equation,
a recent large-scale study of the general population has shown that individuals with eGFR60
ml/min/1.73m2 have a significant risk for developing end-stage kidney disease, if they exhibit
more than 30% eGFR reduction in 2 or 3 years. Therefore, the use of the eGFR equation to
investigate the risk factors for kidney dysfunction in patients with eGFR60 ml/min/1.73m2
could be meaningful [9,20]. Furthermore, only a few reports have investigated the prognostic
factors for the decline in eGFR in the general population without CKD, probably because of
eGFR uncertainty in this population. Therefore, our study can trigger the start of revealing
hidden risk factors for kidney dysfunction in the general population with eGFR60 mL/min/
1.73m2 using the eGFR equation.
Conclusions
It is important to measure U-Col4CR even in the general population without diabetes, because
abnormal U-Col4CR can be a risk factor for the decline in eGFR in individualis without diabe-
tes and with normal kidney function and urinalysis findings. U-Col4CR measurement can
help detect future complications such as diabetic kidney disease.
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